Press Releases

PARIS--(BUSINESS WIRE)-- Regulatory News:

In accordance with Article 5 of EU Regulation n° 596/2014 (Market Abuse Regulation), detailed information is available on the website of Tikehau Capital (Paris: TKO): https://www.tikehaucapital.com/fr/shareholders/regulatory-information

Disclosure of shares repurchases from 24 May 2024 to 30 May 2024

Name of the issuer

Issuer Identity Code (LEI)

Trading Day

ISIN

Aggregated... (continue reading...)

Toronto, Ontario--(Newsfile Corp. - May 31, 2024) - Pedro Resources Ltd. (CSE: VBN) ("Pedro" or the "Company") announces that Jacqueline Wilkie, the current Chief Executive Officer and a director of the Company has been appointed as Interim Chief Financial Officer effective immediately replacing Ms. Albina Manaj. The Company is currently conducting a thorough search for a new Chief Financial Officer with the expertise and leadership qualities to guide the Company... (continue reading...)

SAN DIEGO, May 31, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased Cambium Networks Corporation (NASDAQ: CMBM) securities between May 8, 2023 and January 18, 2024. Cambium, together with its subsidiaries, engages in the design, development, and manufacture of wireless broadband and Wi-Fi networking infrastructure solutions.

For more information, submit a form, ... (continue reading...)

New York, New York--(Newsfile Corp. - May 31, 2024) - For 15 years, WSN has provided resourcing and strategic consulting globally for a variety of industries with notable success among the largest global financial institutions.WSN Consultingnow sets to expand its practice into the Consumer Products sector.

Alex Ciccotelli and Andrew Lederman of WSN Consulting

"Consumer Products are a natural expansion for WSN, our global footprint and years of successful execution of... (continue reading...)

Vivacelle is advancing a robust pipeline of therapies for shock and trauma-induced conditions

Vivacelle's pipeline is led by VBI-S, a Phase 3-ready asset designated for the treatment of hypotension and hypovolemia in septic shock patients, and VBI-1, a Phase 2-ready candidate for hemorrhagic shock. 

KANSAS CITY, Mo., May 31, 2024 /PRNewswire/ -- Vivacelle Bio, a late-stage biopharma company developing life-saving treatments for shock and trauma, today announced that... (continue reading...)